S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study
Anita Afzali, Walter Reinisch(Medical University of Vienna), Mary Ellen Frustaci(Johnson & Johnson (United States)), Zijiang Yang(Henan Medical University), William J. Sandborn(University of San Diego), Tadakazu Hisamatsu(Kyorin University), Jane M. Andrews(Health Net), Brian G. Feagan(Western University), Kathleen Weisel, Susana Gonzalez, Chenglong Han(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Matthew Germinaro(Johnson & Johnson (United States))
Cited by 2
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k